Piper Sandler initiated coverage on Labcorp Holdings Inc. with a new price target
$LH
Medical Specialities
Health Care
Piper Sandler initiated coverage of Labcorp Holdings Inc. with a rating of Neutral and set a new price target of $235.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/10/2025 | $260.00 | Buy → Hold | HSBC Securities |
| 4/2/2025 | $276.00 | Buy | Redburn Atlantic |
| 3/4/2025 | $250.00 → $300.00 | Neutral → Buy | Citigroup |
| 1/7/2025 | $260.00 → $265.00 | In-line → Outperform | Evercore ISI |
| 12/10/2024 | $265.00 → $275.00 | Buy | Jefferies |
| 10/30/2024 | Hold → Buy | HSBC Securities | |
| 10/1/2024 | $235.00 | Neutral | Piper Sandler |
| 3/25/2024 | $250.00 | Hold → Buy | Argus |
BURLINGTON, N.C., Jan. 15, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter of 2025 before the market opens on Tuesday, February 17, 2026. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Partici
BURLINGTON, N.C., Jan. 14, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 12, 2026, to stockholders of record as of the close of business on February 27, 2026. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and c
Molecular residual disease (MRD) testing detects cancer recurrence months before traditional imagingLabcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA non-small cell lung cancer and stage III colon cancerBURLINGTON, N.C., Jan. 13, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the continued expansion of its molecular residual disease (MRD)i portfolio designed to help clinicians detect cancer recurrence earlier than traditional imaging. The expanded offerings include Labcorp Plasma Detect ID, a whole exome sequence-guided, personalized panel for patients with stage I–III bre
8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
HSBC Securities downgraded Labcorp Holdings Inc. from Buy to Hold and set a new price target of $260.00
Redburn Atlantic initiated coverage of Labcorp Holdings Inc. with a rating of Buy and set a new price target of $276.00
Citigroup upgraded Labcorp Holdings Inc. from Neutral to Buy and set a new price target of $300.00 from $250.00 previously
3 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
3 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
3 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
Bulto, President, U.S. of Novartis, brings global healthcare leadership and growth track record to support Labcorp's long-term strategy BURLINGTON, N.C., Nov. 24, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of Victor Bulto, a seasoned pharmaceutical executive and member of Novartis' executive leadership team, to its Board of Directors, effective December 1, 2025. Bulto is an accomplished global executive with 25 years of experience in healthcare, and a proven track record of leadin
ARLINGTON, Va., July 08, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced the appointment of Lance V. Berberian to its Board of Directors, effective July 15, 2025. He has also been named a member of the Audit Committee of the Board. Following the appointment of Mr. Berberian, the Board will comprise 10 directors. "We are excited to welcome Lance to our Board of Directors," said David King, Chairman of the Board, Privia Health Group, Inc. "Lance brings extensive technology strategy and digital transformation experience to the Board, including IT governance, infrastructure management and cybersecurity. We believe his expertise will be invaluable to Privia Health as
SOLVD Health (SOLVD), a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has appointed diagnostics pioneer Mike Aicher and strategic advisor Vince Cebula to its Board of Directors. Their combined leadership in molecular diagnostics, healthcare technology, and growth-stage investment will support the company's continued expansion as it scales access to personalized health insights and accelerates development of its precision diagnostics platform. Aicher's expertise in building and scaling diagnostic platforms will be instrumental as SOLVD Health expands its personalized health solutions. He brings more than three decades of executiv
BURLINGTON, N.C., Jan. 15, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter of 2025 before the market opens on Tuesday, February 17, 2026. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Partici
BURLINGTON, N.C., Jan. 14, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 12, 2026, to stockholders of record as of the close of business on February 27, 2026. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and c
TOLEDO, Ohio, Jan. 8, 2026 /PRNewswire/ -- NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has completed the acquisition of the Early Development medical device testing business of Labcorp (NYSE:LH), a leading provider of innovative and comprehensive laboratory services. This strategic move underscores NAMSA's commitment to advancing innovation and accelerating time-to-market for MedTech manufacturers worldwide. As a result of the acquisition, NAMSA assumes the U.S. portfolio of services of Labcorp's Ear
SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)
SC 13D/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Filed by)
SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)